Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients.

Rehman KU, Akhtar T, Sabar MF, Tariq MA.

Exp Ther Med. 2015 Jul;10(1):309-315. Epub 2015 May 14.

2.

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use.

Norgard NB, DiNicolantonio JJ.

Ther Adv Chronic Dis. 2015 Jul;6(4):204-18. doi: 10.1177/2040622315584113. Review.

3.
4.

Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping.

Fontana P, Cattaneo M, Combescure C, Reny JL.

J Am Heart Assoc. 2013 Mar 27;2(2):e000131. doi: 10.1161/JAHA.112.000131.

5.

Clinically relevant genetic variations in drug metabolizing enzymes.

Pinto N, Dolan ME.

Curr Drug Metab. 2011 Jun;12(5):487-97. Review.

6.

Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution.

Chen H, Yu G, Sun H, Wu X, Wang H.

Evid Based Complement Alternat Med. 2011;2011:207034. doi: 10.1155/2011/207034. Epub 2011 Mar 1.

7.
8.

Clopidogrel pathway.

Sangkuhl K, Klein TE, Altman RB.

Pharmacogenet Genomics. 2010 Jul;20(7):463-5. doi: 10.1097/FPC.0b013e3283385420. No abstract available.

9.

Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.

Oestreich JH, Holt J, Dunn SP, Smyth SS, Campbell CL, Charnigo R, Akers WS, Steinhubl SR.

Coron Artery Dis. 2009 May;20(3):207-13. doi: 10.1097/MCA.0b013e328329924b.

Supplemental Content

Support Center